ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

autogene cevumeran

Also written as “Autogene cevumeran”, “Autogene Cevumeran” and “RO7198457 intravenous (IV)”.

Its studies are mostly in Melanoma · Colorectal Neoplasms · Adenocarcinoma, led by 2 companies.

Drug pageAutogene cevumeran: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Jan 7, 20195 company-led studies, 3 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Rocheits history only42 open or runningphase 2since Jan 7, 2019Sep 19, 2017Nov 10, 2027phase 2 · NCT06534983
BioNTechits history only11 open or runningphase 2since Jul 20, 2020Jul 20, 2020Nov 2026phase 2 · NCT04486378
  • Named in Hoffmann-La Roche’s own pipeline as RG6180 autogene cevumeran (BioNTech), phase 2, as of Oct 22, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 19, 2017First study: phase 1 study in MelanomaNew to Hoffmann-La RocheHoffmann-La Roche · NCT03289962 · 273 enrolled · United States, Belgium, Canada and more
  2. Jan 7, 2019Phase 2 study in Advanced MelanomaHoffmann-La Roche · NCT03815058 · 131 enrolled · United States, Australia, Belgium and more
  3. Dec 9, 2019Named autogene cevumeranINNProposed as its International Nonproprietary Name in WHO's List 122
  4. Jul 20, 2020BioNTech’s first study: phase 2 study in Colorectal NeoplasmsNew to BioNTechBioNTech · NCT04486378 · 327 enrolled · United States, Belgium, Canada and more
  5. Jul 21, 2023Phase 2 study in AdenocarcinomaHoffmann-La Roche · NCT05968326 · 260 enrolled · United States, Belgium, Canada and more
  6. Jul 30, 2024Phase 2 study in Muscle-invasive Urothelial CarcinomaHoffmann-La Roche · NCT06534983 · 62 enrolled · United States, Argentina, Australia and more

Ahead

  1. Nov 2026Primary completion: phase 2 study in Colorectal NeoplasmsBioNTech · NCT04486378
  2. Nov 10, 2027Primary completion: phase 2 study in Muscle-invasive Urothelial CarcinomaHoffmann-La Roche · NCT06534983
  3. Jan 1, 2031Primary completion: phase 2 study in AdenocarcinomaHoffmann-La Roche · NCT05968326

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“An mRNA-based individualized, therapeutic cancer vaccine targeting an unspecified amount of tumor-associated antigens (TAAs) that are specifically expressed in the patient's cancer, with potential immunostimulatory and antineoplastic activities. Upon administration, autogene cevumeran is taken up…”NCIt, read by Claude

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06534983Muscle-invasive Urothelial Carcinoma · United States, Argentina, Australia and more2Active, not recruitingHoffmann-La RocheNov 10, 202762
NCT05968326Adenocarcinoma · United States, Belgium, Canada and more2Active, not recruitingHoffmann-La RocheJan 1, 2031260
NCT04486378Colorectal Neoplasms · United States, Belgium, Canada and more2Active, not recruitingBioNTechNov 2026327
NCT03815058Advanced Melanoma · United States, Australia, Belgium and more2CompletedHoffmann-La RocheJan 21, 2025131
NCT03289962Melanoma · United States, Belgium, Canada and more1CompletedHoffmann-La RocheJul 1, 2025273

How it is read

Names in the registry

  • “Autogene cevumeran”, 3 entries
  • “Autogene Cevumeran”, 1 entry
  • “RO7198457 intravenous (IV)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.